Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
Results of a recent industry wide survey show that biopharmaceutical companies are planning to make a gradual increase in investment in new, predictive safety technologies. While 53% of respondents say their organization’s spending levels will remain “about the same,” 26% claim they will increase their spending. The types of technologies that are generating the most interest (and investment) from biopharmaceutical companies are:
- High content toxicity assessment assays or high throughput cell health profiles
- Mechanistic or predictive toxicogenomics
- Toxicity biomarkers
The four technology types that will be attracting the vast majority of “assessment resources” (resources dedicated to due diligence and evaluation of novel technologies) are:
- Three-dimensional matrix of human hepatocytes/stem cells for toxicity assessment
- Assays to detect risk of idiosyncratic liver toxicity
- Mechanistic or predictive toxicogenomics
- Systems toxicology or modeling of toxic pathways
--|--EventPDF--||--
Presenters:
Ernie Bush
Director of Collaborative Projects
Drug Safety Executive Council (DSEC)
